Cytokinetics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 113.75, 399.51, 865.51, 1451.88, 2175.91 ], "ebit_estimate": [ -746.06, -558.24, -261.11, 185.56, 872.79 ], "ebitda_estimate": [ -732.21, -537.79, -369.35, 563.83, null ], "net_income_estimate": [ -826.46, -634.28, -345.7, 86.04, 620.06 ], "per_share_eps_estimate": [ -6.3, -4.64, -2.27, 0.57, 4.91 ], "eps_nri_estimate": [ -6.4, -4.71, -2.3, 0.57, 4.91 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ -1.72, -0.52, 4.19, null, null ], "pretax_income_estimate": [ -822.14, -643.67, -364.6, 82.07, 649.68 ], "operating_cash_flow_per_share_estimate": [ -4.44, -2.45, -0.69, null, null ], "roa_estimate": [ -47.8, -27.6, 0.9, null, null ], "roe_estimate": [ 220.1, 101.1, -63.77, null, null ], "gross_margin_estimate": [ 94.6, 93.37, 93.27, 91.07, 91.2 ], "operating_cash_flow_estimate": [ -547.74, -302.02, -85.06, null, null ], "pettm_estimate": [ 0, 0, 0, 148.63, 17.27 ], "long_term_growth_rate_mean": 29.16, "long_term_revenue_growth_rate_mean": "125.08", "future_per_share_eps_estimate_growth": 29.37, "future_eps_nri_estimate_growth": 29.16, "future_revenue_estimate_growth": 125.08, "future_ebit_estimate_growth": 24.77, "future_ebitda_estimate_growth": 16.26, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 23.85, "future_pretax_income_estimate_growth": 22.47, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -2.2, "future_operating_cash_flow_per_share_estimate_growth": 45.39 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 16.97, 27.7, 45.31, 55.87, 80.63, 109, 153.75, null ], "ebit_estimate": [ -193.84, -192.66, -184.01, -167.88, -155.42, -138.78, -101.23, null ], "ebitda_estimate": [ -193.25, -196.94, -188.73, -178.34, -107.5, -96.99, null, null ], "net_income_estimate": [ -214.39, -213.29, -204.96, -176.86, -182.32, -165.02, -126.6, null ], "per_share_eps_estimate": [ -1.63, -1.57, -1.49, -1.35, -1.38, -1.22, -0.91, null ], "eps_nri_estimate": [ -1.65, -1.58, -1.48, -1.54, -1.38, -1.22, -0.91, -1.36 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -213.94, -211.54, -205.96, -188.96, -182.32, -165.02, -126.6, null ], "operating_cash_flow_per_share_estimate": [ -1.56, -1.45, -2.55, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 93, 93.75, 94.63, 95, 95, 95, 95, null ], "operating_cash_flow_estimate": [ -192.31, -178.75, -314.35, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": 29.16, "long_term_revenue_growth_rate_mean": "125.08", "future_per_share_eps_estimate_growth": 29.37, "future_eps_nri_estimate_growth": 29.16, "future_revenue_estimate_growth": 125.08, "future_ebit_estimate_growth": 24.77, "future_ebitda_estimate_growth": 16.26, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 23.85, "future_pretax_income_estimate_growth": 22.47, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -2.2, "future_operating_cash_flow_per_share_estimate_growth": 45.39 }